A cannabidiol vaporiser that has helped thousands of consumers suffering from a variety of conditions is being tested by an NHS unit, an unprecedented step that could increase scrutiny on cannabis’ medical benefits and have a huge impact on the UK’s draconian legislation around it.
The MediPen, a completely legal way to consume CBD, which, unlike THC, is completely non-psychoactive, has been on sale for a year now and drawn very positive reviews, relieving the pain of people with everything from depression and anxiety to arthritis and fibromyalgia.
The company told The Independent it has been consulting with a group of production and regulatory support pharmacists from the NHS for a few months now, who have been testing their proprietary cannabis oil formulation.
A detailed public report outlining the testing process and extraction methodology will follow, and though it is only about confirming purity and cannabinoid profile at this stage, this is a big first step for the medical cannabis industry in the UK.
MediPen is confident that by setting a precedent for testing cannabis products with a reputable body like the NHS, it will have a huge impact on the public’s perception of cannabis.